Neuberger Berman Group LLC grew its stake in Biohaven Ltd. (NYSE:BHVN - Free Report) by 2,953.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 129,465 shares of the company's stock after buying an additional 125,225 shares during the period. Neuberger Berman Group LLC owned 0.13% of Biohaven worth $4,836,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds have also recently added to or reduced their stakes in BHVN. Vanguard Group Inc. grew its position in Biohaven by 8.1% in the 4th quarter. Vanguard Group Inc. now owns 8,414,120 shares of the company's stock valued at $314,267,000 after purchasing an additional 628,211 shares during the period. JPMorgan Chase & Co. lifted its position in Biohaven by 144.5% in the 4th quarter. JPMorgan Chase & Co. now owns 1,979,169 shares of the company's stock valued at $73,922,000 after acquiring an additional 1,169,721 shares in the last quarter. Geode Capital Management LLC boosted its stake in Biohaven by 11.1% during the 4th quarter. Geode Capital Management LLC now owns 1,905,366 shares of the company's stock valued at $71,182,000 after purchasing an additional 190,754 shares during the last quarter. ARS Investment Partners LLC increased its holdings in Biohaven by 1.0% during the 4th quarter. ARS Investment Partners LLC now owns 1,040,712 shares of the company's stock worth $38,871,000 after purchasing an additional 10,473 shares in the last quarter. Finally, Norges Bank purchased a new stake in shares of Biohaven in the fourth quarter worth approximately $33,711,000. Institutional investors own 88.78% of the company's stock.
Insider Buying and Selling at Biohaven
In other Biohaven news, Director John W. Childs bought 32,700 shares of the firm's stock in a transaction on Tuesday, March 4th. The shares were acquired at an average cost of $30.47 per share, with a total value of $996,369.00. Following the purchase, the director now directly owns 2,320,571 shares of the company's stock, valued at $70,707,798.37. This trade represents a 1.43 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. 16.00% of the stock is owned by corporate insiders.
Biohaven Stock Performance
Biohaven stock traded up $0.76 during midday trading on Thursday, hitting $19.44. 519,858 shares of the company's stock were exchanged, compared to its average volume of 1,113,832. The firm has a 50-day moving average of $29.23 and a two-hundred day moving average of $38.98. Biohaven Ltd. has a 12 month low of $15.79 and a 12 month high of $55.70. The company has a market cap of $1.98 billion, a PE ratio of -2.08 and a beta of 1.33.
Biohaven (NYSE:BHVN - Get Free Report) last released its earnings results on Monday, March 3rd. The company reported ($1.85) earnings per share for the quarter, missing the consensus estimate of ($1.56) by ($0.29). As a group, equities analysts expect that Biohaven Ltd. will post -8.9 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Several equities research analysts have commented on the stock. Deutsche Bank Aktiengesellschaft set a $60.00 price objective on shares of Biohaven and gave the company a "buy" rating in a research note on Thursday, March 20th. JPMorgan Chase & Co. cut their price objective on shares of Biohaven from $72.00 to $68.00 and set an "overweight" rating for the company in a report on Wednesday, March 5th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $61.00 price target on shares of Biohaven in a report on Tuesday, March 4th. HC Wainwright reissued a "buy" rating and set a $54.00 price objective on shares of Biohaven in a report on Tuesday, March 4th. Finally, Morgan Stanley lowered their price target on shares of Biohaven from $69.00 to $63.00 and set an "overweight" rating on the stock in a report on Friday, March 7th. Fourteen equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Biohaven has a consensus rating of "Buy" and a consensus price target of $62.77.
Get Our Latest Research Report on Biohaven
About Biohaven
(
Free Report)
Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.
Featured Stories
Before you consider Biohaven, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biohaven wasn't on the list.
While Biohaven currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
